Searched for
GREVLIMID SALES FORECAST
DRL gears up for biosimilar push, consumer health growth post record FY25Dr Reddy’s stock rose 5.5% in six sessions post-Q4 results, outperforming the BSE Healthcare index. Strong revenue growth, biosimilar launc...20 May, 2025, 05.59 AM IST- Dr Reddy’s Labs Q4 Preview: PAT may jump up to 12% YoY, revenue to rise up to 18% on generics business doseDr Reddy’s Q4FY25 net profit is expected to grow 1.3–12% YoY, with revenues likely rising 13–18% to ₹7,981–8,424 crore, according to broker...08 May, 2025, 08.12 PM IST
- Dr. Reddy's Q3 Preview: PAT may rise 10% YoY; US sales to be stableDr. Reddy's net profit for the third quarter is expected to grow 10% YoY, with revenues likely increasing 13% YoY, based on an average of f...22 Jan, 2025, 07.24 PM IST
- Pharma Q2 Preview: Cipla to see steady quarter; higher profit and revenue growth for Dr Reddy'sCipla could deliver healthy growth of 5% in the Indian business in the second quarter, but the US business is likely to witness pressure on...26 Oct, 2023, 04.36 PM IST
- Q1 earnings: 26 companies that may report over 100% jump in profitDomestic brokerage Motilal expects Nifty earnings to grow 25% YoY in Q1. Oil and gas sector may report a 3x surge in profit YoY underpinned...10 Jul, 2023, 10.32 AM IST
- Stock screener: MFs, FIIs drool over these 10 stocks, earn double-digit returnsInstitutional investors such as foreign portfolio investors and mutual funds have increased their stakes in at least 20 Indian stocks in th...09 Jun, 2023, 12.28 PM IST
- DRL Q3 Results Preview: Profit may grow 25% YoY; margin likely to fallEdelweiss sess profit rising 26.5 per cent YoY to Rs 780 crore. It sees sales rising 12.2 per cent YoY to Rs 5,531 crore. The brokerage see...28 Jan, 2022, 09.47 AM IST
Load More
